Literature DB >> 33784832

Embolic Stroke of Undetermined Source and Patent Foramen Ovale: Risk of Paradoxical Embolism Score Validation and Atrial Fibrillation Prediction.

Davide Strambo1, Gaia Sirimarco1, Stefania Nannoni1, Kalliopi Perlepe2, George Ntaios2, Kostantinos Vemmos3, Patrik Michel1.   

Abstract

Background and Purpose: The Risk of Paradoxical Embolism (RoPE) score stratifies patients with stroke according to the probability of having a patent foramen ovale (PFO), which (through Bayes theorem and simple assumptions) can be used to estimate the probability that a PFO is pathogenic in a given subgroup of patients with specific features (ie, a given RoPE score value): a higher PFO prevalence corresponds to a higher probability that a PFO is pathogenic. Among alternative mechanisms in embolic stroke of undetermined source (ESUS), the actual stroke cause may be covert atrial fibrillation. We aimed to validate the RoPE score in a large ESUS population and investigate the rate of stroke recurrence and new incident atrial fibrillation during follow-up according to PFO status and RoPE score.
Methods: We pooled data of consecutive patients with ESUS from 3 prospective stroke registries. We assessed RoPE score’s calibration and discrimination for the presence of PFO (and consequently for the probability that it is pathogenic). Multivariate logistic regression analysis was performed to identify factors associated with PFO.
Results: Among 455 patients with ESUS (median age 59 years), 184 (40%) had PFO. The RoPE score’s area under the receiver operating characteristic curve was 0.75. In addition to RoPE score variables, absence of left ventricular hypertrophy, absence of atherosclerosis, and infratentorial lesions were independently associated with PFO. In patients with PFO and RoPE 7 to 10, PFO and RoPE 0 to 6, and without PFO, new incident atrial fibrillation rate was 3.1%, 20.5%, and 31.8%, respectively (log-rank test=6.28, P=0.04). Stroke recurrences in patients with likely pathogenic PFO were not statistically different from other patients. Conclusions: This multicenter study validates the RoPE score to predict the presence/absence of PFO in patients with ESUS, which strongly suggests that RoPE score is helpful in identifying patients with ESUS with pathogenic versus incidental PFOs. Left ventricular hypertrophy, atherosclerosis, and infratentorial stroke may further improve the score. Low RoPE scores were associated with more incidental atrial fibrillation during 10-year follow-up.

Entities:  

Keywords:  Bayes theorem; atrial fibrillation; embolic stroke; foramen ovale, patent; prevalence

Mesh:

Year:  2021        PMID: 33784832     DOI: 10.1161/STROKEAHA.120.032453

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

1.  Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.

Authors:  Victor J Del Brutto; Han-Christoph Diener; J Donald Easton; Christopher B Granger; Lisa Cronin; Eva Kleine; Claudia Grauer; Martina Brueckmann; Kazunori Toyoda; Peter D Schellinger; Philippe Lyrer; Carlos A Molina; Aurauma Chutinet; Christopher F Bladin; Conrado J Estol; Ralph L Sacco
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

2.  Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.

Authors:  David M Kent; Jeffrey L Saver; Scott E Kasner; Jason Nelson; John D Carroll; Gilles Chatellier; Geneviève Derumeaux; Anthony J Furlan; Howard C Herrmann; Peter Jüni; Jong S Kim; Benjamin Koethe; Pil Hyung Lee; Benedicte Lefebvre; Heinrich P Mattle; Bernhard Meier; Mark Reisman; Richard W Smalling; Lars Soendergaard; Jae-Kwan Song; Jean-Louis Mas; David E Thaler
Journal:  JAMA       Date:  2021-12-14       Impact factor: 157.335

Review 3.  Heart-Brain Relationship in Stroke.

Authors:  Roger E Kelley; Brian P Kelley
Journal:  Biomedicines       Date:  2021-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.